Keros Therapeutics (NASDAQ:KROS) Rating Lowered to “Strong Sell” at Wall Street Zen

Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Sunday.

Several other equities analysts also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Wells Fargo & Company decreased their target price on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Zacks Research lowered shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Leerink Partners cut their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $20.50.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $10.48 on Friday. The firm has a market capitalization of $207.82 million, a PE ratio of -2.83 and a beta of 0.99. The business has a 50 day simple moving average of $10.64 and a two-hundred day simple moving average of $12.00. Keros Therapeutics has a 1 year low of $9.69 and a 1 year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. Equities research analysts expect that Keros Therapeutics will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 10,958 shares in the company, valued at $117,579.34. This trade represents a 19.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the sale, the director directly owned 9,767 shares of the company’s stock, valued at approximately $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,425 shares of company stock valued at $89,994 over the last quarter. 12.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Keros Therapeutics during the second quarter valued at $29,898,000. Vanguard Group Inc. lifted its stake in Keros Therapeutics by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock worth $43,011,000 after acquiring an additional 87,129 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in Keros Therapeutics by 26.6% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock worth $15,645,000 after acquiring an additional 161,336 shares during the period. Goldman Sachs Group Inc. grew its holdings in Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares in the last quarter. Finally, Federated Hermes Inc. grew its holdings in Keros Therapeutics by 27.3% during the 4th quarter. Federated Hermes Inc. now owns 654,724 shares of the company’s stock worth $13,330,000 after acquiring an additional 140,564 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.